Saturday, May 23, 2026 1:14:34 PM
"Baxter, your commentary perfectly captures the textbook definition of retail naivety. You genuinely believe that after a company survives a decade-long siege and a historic market-maker ambush, a CEO is just going to march right back into the same domestic OTC cesspool, pull the lever, and expect a fair result. That isn't a strategy; it’s a delusion.
Let’s look at the actual graphic reality of what is happening:
The Insanity Loop: You are waiting for a fair launch on a domestic tape controlled by entities whose entire survival depends on keeping this asset pinned. Expecting them to just 'let it fly' because of good news ignores the basic mechanics of predatory shorting. They are hell-bent on destruction because their liabilities leave them no choice.
The Structural Firewall: Linda Powers openly stated after the May 2022 ambush, 'I will never let them hurt my company again.' Moving the primary footprint to the LSE and locking down UK manufacturing isn't just an expansion—it's a clinical de-coupling. The LSE operates under strict Crest settlement and central clearing rules that don't tolerate the infinite synthetic 'naked fail' loops of the OTC sandbox.
Changing the Gravity: While you sit there counting pennies on a manipulated domestic sheet, the operational reality is being hardcoded into a completely different jurisdiction. Setting up localized collection, Advent Sawston, and secondary GMP collaborations is how you build a business where sovereign wealth and European funds can interface directly with the asset—totally insulated from domestic market-maker arbitrage.
The US legal team is handling the historical wreckage through the courts, but the commercial future is being built where the predators don't control the gravity. You're watching the rearview mirror wondering why the car isn't moving; she already changed the vehicle."
Let’s look at the actual graphic reality of what is happening:
The Insanity Loop: You are waiting for a fair launch on a domestic tape controlled by entities whose entire survival depends on keeping this asset pinned. Expecting them to just 'let it fly' because of good news ignores the basic mechanics of predatory shorting. They are hell-bent on destruction because their liabilities leave them no choice.
The Structural Firewall: Linda Powers openly stated after the May 2022 ambush, 'I will never let them hurt my company again.' Moving the primary footprint to the LSE and locking down UK manufacturing isn't just an expansion—it's a clinical de-coupling. The LSE operates under strict Crest settlement and central clearing rules that don't tolerate the infinite synthetic 'naked fail' loops of the OTC sandbox.
Changing the Gravity: While you sit there counting pennies on a manipulated domestic sheet, the operational reality is being hardcoded into a completely different jurisdiction. Setting up localized collection, Advent Sawston, and secondary GMP collaborations is how you build a business where sovereign wealth and European funds can interface directly with the asset—totally insulated from domestic market-maker arbitrage.
The US legal team is handling the historical wreckage through the courts, but the commercial future is being built where the predators don't control the gravity. You're watching the rearview mirror wondering why the car isn't moving; she already changed the vehicle."
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
